Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9450969 | 0.82 | CA12 (0.46) | NLRP3 | |
| SCHEMBL9156040 | 0.78 | GABRA1 (0.41) | — | |
| SCHEMBL9723542 | 0.78 | NLRP3 (0.55) | NLRP3LMNAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL9723490 | 0.75 | NLRP3 (0.52) | NLRP3LMNAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL8819876 | 0.74 | KMT2A (0.61) | NLRP3LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL28188485 | 0.74 | NLRP3 (0.81) | NLRP3LMNAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19853203 | 0.74 | NLRP3 (0.55) | NLRP3LMNAKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL6429941 | 0.74 | KMT2A (0.65) | NLRP3LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL462304 | 0.74 | LPAR1 (0.66) | NLRP3LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL3955253 | 0.73 | KMT2A (0.59) | NLRP3LMNAKMT2ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| EP-0556308-B1 | OXYSULFONYL UREA ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1995-02-01 | — | — | EP | claimed |
| EP-0556308-A1 | OXYSULFONYL UREA ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | claimed |
| WO-1992008692-A1 | OXYSULFONYL UREA ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0556308-B1 | OXYSULFONYL UREA ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5364882-A | Acyloenzyme a: cholesterol acyltransferase inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0556308-A1 | OXYSULFONYL UREA ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | disclosed |
| US-5198466-A | Acylcoenzyme A Inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| WO-1992008692-A1 | OXYSULFONYL UREA ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | NLRP3 1677/4885LMNA 2706/4885KMT2A 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.